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Causes of Death in the Antiarrhythmics
Versus Implantable Defibrillators (AVID) Trial
The AVID Investigators
OBJECTIVES This study analyzed the causes of death in the Antiarrhythmics Versus Implantable
Defibrillators (AVID) Trial.
BACKGROUND Both implantable cardioverter-defibrillators (ICDs) and antiarrhythmic drugs (AADs) are
used as mainstays of treatment for life-threatening ventricular arrhythmias in patients who
have survived either ventricular fibrillation or sustained ventricular tachycardia with hemo-
dynamic compromise and serious symptoms. The AVID Trial compared the effectiveness of
these two therapies. Survival was better with the ICD. Assessment of the cause of death
should help to determine the mechanism of improvement in survival with the ICD.
METHODS Of 1,016 patients enrolled in the AVID Trial, 202 patients died. The mode of death was
determined by the unblinded Principal Investigator and independently by an Events
Committee, which reviewed materials meticulously blinded with respect to treatment. Deaths
were classified as cardiac or noncardiac. Cardiac deaths were further classified as arrhythmic
or nonarrhythmic, and causes of noncardiac death were identified.
RESULTS Deaths were more frequent in patients treated with an AAD (n 5 122), compared with
patients treated with the ICD (n 5 80), unadjusted p , 0.001, p 5 0.012 adjusted for
sequential monitoring. In AVID, 157 deaths were cardiac, and 79 were arrhythmic. The
major effect of the ICD was to prevent arrhythmic death (AAD 5 55, ICD 5 24, nominal
unadjusted p , 0.001). Nonarrhythmic cardiac deaths were equal (AAD 5 39, ICD 5 39).
Patients treated with an AAD had a slightly greater incidence of noncardiac deaths (28 vs. 17,
p 5 0.053), primarily due to pulmonary and renal causes.
CONCLUSIONS The ICD is more effective than an AAD in reducing arrhythmic cardiac death, while
nonarrhythmic cardiac death is unchanged. Of note, apparent arrhythmic death still seems to
constitute 38% of all cardiac deaths despite treatment with an ICD. However, the ICD
remains superior to an AAD in prolonging survival after life-threatening arrhythmias. (J Am
Coll Cardiol 1999;34:1552–9) © 1999 by the American College of Cardiology
The implantable cardioverter-defibrillator (ICD) is de-
signed to terminate life-threatening ventricular arrhythmias
(1). These devices can also pace to control serious brady-
cardias. Thus, ICDs should prevent only deaths due to
arrhythmias and have no effect on deaths due to other
causes. If other causes of death, such as congestive heart
failure, predominate in any patient population, these com-
peting causes of mortality could diminish or eliminate any
beneficial effect of the ICD compared with drug therapy.
The Antiarrhythmics Versus Implantable Defibrillators
(AVID) Trial (2,3) has demonstrated that the ICD is
superior to an antiarrhythmic drug (AAD) in prolonging
survival for patients who have survived life-threatening
ventricular arrhythmias. At three years, the survival rate for
ICD-treated patients was 84%, compared with 76% for
patients treated with an AAD (p 5 0.02). In this paper, the
causes of death of patients in the AVID Trial are reported.
METHODS
The design of the AVID Trial has been reported (2). It was a
randomized, multicenter comparison of treatment of patients
resuscitated from ventricular fibrillation (VF) or sustained
ventricular tachycardia (VT) that had caused hemodynamic
compromise. Therapy was randomized to either: 1) an ICD or
2) an AAD, primarily amiodarone. All study sites had the
protocol approved by the local Institutional Review Board, and
all patients signed an informed consent.
The first patient was enrolled in June 1993. The study
was terminated in April 1997, when an interim analysis
showed that the ICD was the superior treatment. The
original report (3) described the results based upon all-cause
mortality. Subsequently, all deaths were also classified by
cause. For the purposes of the AVID Trial, the term “death”
was defined as the time when respiration and blood circu-
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lation (pulse) ceased without recovery, that is, the time listed
on a death certificate. Any arrhythmia that reverted spon-
taneously or was converted to a perfusing rhythm by any
technique was not counted as a death. As such, sustained
VT specifically was not included. Likewise, a cardiac arrest
in which the patient was successfully resuscitated was not
counted as a death but simply as a recurrent arrhythmia. In
addition, patients whose resuscitation yielded a comatose,
unresponsive or vegetative condition were also not included
as a death, until the patient’s pulse and respiration ulti-
mately ceased. The time of brain death was not considered
to be relevant in our analysis.
For each death event, the Principal Investigator com-
pleted a death form that categorized the terminal event in
detail. Data on this form included the timing of events
leading to death, the date and time of clinical death,
symptoms before loss of consciousness, associated symp-
toms, current medications, documentation of rhythm asso-
ciated with the event (if rhythm monitoring occurred),
summary cause of death (cardiac vs. noncardiac), cause of
cardiac death (arrhythmic vs. nonarrhythmic), evidence of
congestive heart failure (CHF) or shock, evidence of myo-
cardial ischemia or myocardial infarction (MI), recent sur-
gery, recent invasive cardiac therapeutic or diagnostic pro-
cedure and the opinion of the Principal Investigator
whether this patient would have survived for four months if
a terminal arrhythmia had not occurred (to distinguish the
patient whose terminal arrhythmia was simply the result of
end-stage heart failure). Furthermore, the Principal Inves-
tigator explained the circumstances surrounding the death
in a detailed letter to the Clinical Trial Center, including a
description of the documented and/or presumed sequence
of arrhythmias and events from information obtained from
relatives, bystanders or other persons who might have
witnessed the event. Detailed data were obtained that
included prehospital notes, emergency room notes, all avail-
able electrocardiograms (ECGs) and rhythm strips, hospital
notes (including the admission history and physical exami-
nation, plus a minimum of the last three days of physicians’
progress notes), nurses’ notes for the three days preceding
death, physicians’ orders, drug administration notes, en-
zyme tests, other relevant laboratory tests, ICD interroga-
tion electrograms and data output, the discharge summary
and an autopsy report (if performed). In addition, the
Clinical Site Coordinator completed a concurrent drugs
form for medications being taken by the patient, and an
ICD evaluation form for patients who had an ICD. If the
patient was hospitalized in conjunction with the event, a
hospitalization form also was completed. Thus, extensive
clinical data regarding the terminal event were obtained.
After the Principal Investigator reviewed and classified
the death, all data were sent to the Clinical Trial Center.
Medical records were then blinded to remove all references
to therapy either with an AAD or the ICD. Furthermore,
“sham-blinding” was performed, in which chart items were
excluded to try to mimic items that would have been deleted
if the patient had been randomized to the alternative arm of
the study. For example, a medication might have been
deleted from an ICD patient’s medication list so that a
blank would appear on that portion of the progress notes.
Therefore, not all patients who had obvious deletions of
drugs in admission notes and progress notes would have
been patients randomized to the drug arm of AVID.
Conversely, patients randomized to the drug arm also had
“sham-blinding” performed by deleting, for example, sen-
tences from X-ray reports to suggest that a description of an
endocardial electrode had been deleted from the X-ray
report. Members of the Events Committee were aware that
“sham-blinding” could occur.
A single member of the Events Committee reviewed each
blinded death event without prior knowledge of the death
classification by the site’s Principal Investigator. If the
Events Committee Reviewer agreed completely with the
Principal Investigator, no further review occurred. If dis-
agreement in classification existed, the event was reviewed
by the entire Events Committee, consisting of three cardi-
ologists experienced in Events Committee deliberations.
Determination of cause of death was made by consensus.
The Events Committee classification was final, except in
three cases categorized as “unable to classify” as cardiac or
noncardiac by the Events Committee, in which case the
Principal Investigators’ determinations were used. In one
other case, classified as cardiac both by the Events Com-
mittee and the Principal Investigator, the Events Commit-
tee was unable to determine whether the cardiac death was
arrhythmic or nonarrhythmic, in which case the Principal
Investigator’s judgment of nonarrhythmic was used.
Deaths were classified as cardiac or noncardiac. Cardiac
deaths were subsequently classified as arrhythmic cardiac or
nonarrhythmic cardiac. The assignment of a diagnosis of
arrhythmic cardiac death required the absence of severe
CHF or shock. Furthermore, an arrhythmic cardiac death
was one in which long-term survival was judged to have
been possible, had it not been for the arrhythmia itself.
Whereas the time frame of the events leading to death was
recorded, timing of symptoms was not necessarily a deter-
minant of the mechanism of death. Nonarrhythmic cardiac
deaths were secondary to CHF or shock. If the CHF or
Abbreviations and Acronyms
AAD 5 antiarrhythmic drug
ACE 5 angiotensin-converting enzyme
AVID 5 Antiarrhythmics Versus Implantable
Defibrillators
CHF 5 congestive heart failure
ECG 5 electrocardiogram
ICD 5 implantable cardioverter-defibrillator
MI 5 myocardial infarction
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
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shock was not reversible and the reviewer believed that the
patient would die soon of pump failure, the death was
considered to be cardiac, but nonarrhythmic. In cases where
CHF or shock caused other end-organ failure, a separate
cardiac classification was allowed. The presence or absence
of myocardial ischemia was noted, with evidence for isch-
emia being symptoms, ECG changes or enzyme abnormal-
ities. Patients with MI and death were classified as arrhyth-
mic if end-stage CHF or shock was not present. If the death
in a clinically stable person was unwitnessed (the patient not
being seen or heard for more than 5 min), it was presumed
to be arrhythmic unless evidence to the contrary was
discovered. Patients who died after cardiac surgery were
considered to have had a cardiac death. If death occurred
after a cardiac procedure or operation in which there was an
unbroken string of nonarrhythmic events leading inexorably
downhill, the event was classified as nonarrhythmic cardiac,
even though the terminal item in the sequence might have
been noncardiac, such as sepsis. In all cases, an assessment
of anticipated long-term survivability was crucial. A patient
who was resuscitated from out-of-hospital cardiac arrest but
who died without regaining neurologic function during
hospitalization was considered to have had an out-of-
hospital arrhythmic death. A patient who died from a
pulmonary cause was classified based on whether it could
have been due to amiodarone, even though the data regard-
ing drug administration were blinded. Cases of suspected
amiodarone pulmonary toxicity were then unblinded regarding
whether the patient had actually received amiodarone.
Patients in whom therapy was changed during the study
(crossovers) were included in this analysis, but they were
analyzed in the group to which they were randomized
(intention-to-treat). Because sequential monitoring rules
were based on total mortality, it is not possible to compute
adjusted p values for comparisons of cause-specific out-
comes. Thus, nominal p values (unadjusted for sequential
monitoring) based on the log-rank statistic are provided for
cause-specific deaths.
RESULTS
Mode of death. More deaths occurred in patients assigned to
an AAD (n 5 122), compared with patients treated with an
ICD (n 5 80), p , 0.012, adjusted for sequential monitoring.
The majority (78%) of deaths were classified as cardiac (Table
1), subclassified equally frequently as arrhythmic and nonar-
rhythmic. The onset of terminal symptoms occurred nearly
equally in-hospital versus out-of-hospital (74 patients [47%]
vs. 83 patients [53%], Table 2). Thirty-four deaths were
witnessed arrhythmic events: 15 were asymptomatic (5 ICD,
10 AAD); 12 were .5 min from onset of symptoms to death
(5 ICD, 7 AAD); and 7 were missing data to calculate time
from onset of symptoms to death (4 ICD, 3 AAD). Twenty-
four unwitnessed arrhythmic deaths occurred unexpectedly
during sleep (5 ICD, 19 AAD). Most arrhythmic deaths were
out-of-hospital. Very few patients had evidence of myocardial
ischemia or MI directly related to death. Even with assessment
of multiple markers of ischemia (symptoms, ECGs, enzymes),
only 8 of 78 nonarrhythmic cardiac deaths and 4 of 79
arrhythmic cardiac deaths were associated with suspected
ischemia, 6 of 8 and 1 of 4 with MI documented, respectively.
Noncardiac deaths were more common in the group treated
with an AAD (28 vs. 17, p 5 0.053; relative risk 5 1.78, 95%
confidence interval 5 0.98 to 3.26; Table 3), with deaths due
to cancer and pulmonary disease predominating. Three deaths
were definitively attributed to pulmonary toxicity due to
amiodarone.
Figure 1 depicts survival free of cardiac death, with
noncardiac death censored. Cardiac death was less frequent
in patients treated with an ICD. Survival free of cardiac
death at one and two years was 90.9% and 85.0% in the
ICD group and 85.1% and 81.2% in the AAD group,
respectively (p 5 0.0042).
Figure 2 depicts survival to arrhythmic death, with both
noncardiac and nonarrhythmic cardiac deaths censored.
Survival was 96.6% and 94.2% at one and two years for
patients treated with ICDs and 91.9% and 89.1% for
AADs, respectively (p 5 0.0002). The benefit of the ICD is
most evident in this analysis.
The 24 apparent arrhythmic deaths in patients with an
ICD are of particular interest. Five were unwitnessed and
occurred unexpectedly during sleep; five were witnessed and
occurred within 5 min of onset of symptoms or asymptom-
atic; 10 were unwitnessed but did not occur during sleep and
were classified as presumably arrhythmic. The remaining
four deaths were witnessed and occurred .5 min from the
onset of symptoms. Thus, there was little opportunity to
gather much data about these terminal events. Only seven
had an ICD interrogation after death. In three of seven, the
ICD shocked appropriately but simply failed to convert the
tachyarrhythmia. In four of seven, no shocks were delivered,
and bradycardia may have been the terminal arrhythmia
with the ICD pacing function not preventing death.
Overall, an ICD interrogation was performed after death
in only 17 patients, rendering this method of assessment
generally unhelpful in classifying deaths. Most ICDs were
not interrogated because the physician attending the patient
at the time of death was not the AVID physician and was
unable to interrogate the device or unaware that such
Table 1. Cause of Death
ICD AAD Total
n 507 509 1016
Cardiac death 63 94 157
Arrhythmic 24 55 79
Nonarrhythmic 39 39 78
Noncardiac death 17 28 45
Total 80 122 202
In the three cases where the Events Committee ruled “unable to classify,” the
Principal Investigators’ classifications were used.
AAD 5 antiarrhythmic drug; ICD 5 implantable cardioverter-defibrillator.
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interrogation might be useful. However, in those 17 patients
in whom an interrogation was performed, 10 had been
classified as nonarrhythmic.
Autopsies, performed in only 14 patients, were too
infrequent to be generally useful to aid in classifying the
cause of death.
Figure 3 illustrates that the ICD conferred no survival
benefit for nonarrhythmic cardiac deaths, p 5 0.804 (both
noncardiac and arrhythmic deaths censored). Though pro-
tection against arrhythmic death might be expected to
increase the number of patients with an ICD at risk of
nonarrhythmic cardiac death, such a trend was not seen.
Arrhythmic death was more common, but of borderline
significance (p 5 0.07), in patients whose index arrhythmia
was VF than in patients who initially qualified for AVID with
VT. There was no difference between patients with VF and
VT regarding the length of time until nonarrhythmic cardiac
death (p 5 0.54). Survival free of arrhythmic death for patients
whose presenting arrhythmia was VT was improved by the
ICD (Fig. 4, p 5 0.025), but not as marked as it was for
patients who qualified with VF, where the survival advantage
of the ICD is obvious, with more than twice as many deaths in
the AAD group (Fig. 5, p 5 0.0019). There was no difference
Figure 1. Survival free of cardiac death. Noncardiac deaths are
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Table 3. Cause of Noncardiac Deaths
ICD AAD Total
Cancer 7 4 11
Pulmonary 2 9 11
Amiodarone 0 3 3
Other 2 6 8
Sepsis/infection 4 4 8
Suicide 0 2 2
Stroke/embolism 2 1 3
Renal failure 0 4 4
Bowel perforation 1 1 2
Other 1 3 4
Total 17 28 45
AAD 5 antiarrhythmic drug; ICD 5 implantable cardioverter-defibrillator.
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in the survival between ICD and antiarrhythmic drug for
nonarrhythmic cardiac death in patients with either VT or VF
(p 5 0.72, 0.98, respectively).
Covariates. Table 4 lists the covariates analyzed in AVID
by treatment group. Neither these nor any other factors
analyzed explained the survival benefit seen with the ICD.
Consistency of classification of death. Initial review by the
single Events Committee Member agreed with the Principal
Investigator in 150 of 202 cases (74%). In the 52 disputed cases
reviewed by the entire Events Committee, 50 were decided by
unanimous vote (three to zero), while two were decided by a
two-to-one vote. Table 5 compares the final classification of
the death event between the Principal Investigator and the final
Events Committee determination. Agreement was generally
good between these classifications. In those 147 deaths that
both the Principal Investigator and the Events Committee
agreed were cardiac, the assessment of arrhythmic versus
nonarrhythmic was likewise good, with only 8% disagreement
between the two classifications. After completion of the review
of deaths, the Events Committee examined all disagreements
regarding arrhythmic versus nonarrhythmic causes between the
Events Committee and the Principal Investigator. Six of the 11
disagreements had resulted from the unawareness on the part
of the Principal Investigator that unwitnessed, unexpected
death was to be classified as arrhythmic.
DISCUSSION
The ICD was designed to prevent arrhythmic death. In the
AVID Trial, the ICD decreased arrhythmic death, whereas
nonarrhythmic cardiac death was unaltered. Noncardiac
death was more frequent in the AAD-treated group (p 5
0.053), with the difference primarily an excess of pulmonary
(AAD 5 9, ICD 5 2) and renal (AAD 5 4, ICD 5 0)
deaths in the AAD group.
Comparison with previous studies. The mechanism of
death is frequently difficult to determine in patients with
severe cardiac disease (both coronary disease and left ven-
tricular dysfunction) who are at high risk both for arrhyth-
Figure 2. Survival free of arrhythmic death. Noncardiac and
nonarrhythmic cardiac deaths are censored.
Figure 3. Survival free of nonarrhythmic cardiac death. Noncar-
diac and arrhythmic cardiac deaths are censored.
Figure 4. Survival free of arrhythmic cardiac death in patients who
qualified for AVID with VT. Nonarrhythmic cardiac and noncar-
diac deaths are censored. VT 5 ventricular tachycardia.
Figure 5. Survival free of arrhythmic cardiac death in patients who
qualified for AVID with VF. Nonarrhythmic cardiac and non-
cardiac deaths are censored. VF 5 ventricular fibrillation.
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mic and nonarrhythmic mortality (4–6). Previous nonran-
domized studies have shown the benefit of the ICD in the
reduction of arrhythmic events (7–13), which are usually
thought to be due to either VF or VT degenerating to VF
(though bradycardia deaths may be common in end-stage
heart failure). However, because these studies were not
blinded with respect to ICD therapy, there is a potential for
bias to be introduced by investigator classification of events.
Because most previous ICD studies (7–13) were small or
lacked randomization, patient selection bias may have en-
tered into the choice of therapy and, therefore, the outcome.
Evidence of this bias can be seen in the improvement in
nonarrhythmic or noncardiac death in patients treated with
the ICD. Previous studies also have a significant potential
for event classification bias, where fewer deaths might have
been classified as arrhythmic because of known ICD ther-
apy. Randomized studies, such as AVID, minimize this type
of bias (14–19). In the AVID Trial, the Events Committee
classified events without knowledge of treatment assign-
ment. The Coordinating Center meticulously blinded all
references to arrhythmia treatment from the charts before
review, ensuring an unbiased classification.
Although precise classification of death is always difficult,
in the AVID Trial, agreement in the classification of deaths
between the unblinded Principal Investigator and the
blinded Events Committee was good.
Mechanism of death. In the AVID Trial, the primary end
point (all-cause mortality) was decreased by the ICD. Our
study on the mechanism of death confirms that the majority
of the benefit of the ICD results from the prevention of
death due to arrhythmia, presumably from the treatment of
VT or VF. It is also possible, though unlikely, that antiar-
rhythmic drugs actually increased arrhythmic deaths. The
relative contribution of the beneficial effect of the ICD and
any postulated deleterious effect of an antiarrhythmic drug
cannot be estimated.
Clinical and electrophysiologic differences exist between
patients who have been resuscitated from VF and those who
have experienced sustained VT (20,21). The AVID Trial
further emphasizes this distinction. Patients with a history
of VF were more likely to have an arrhythmic death than
patients with VT. This finding suggests that the substrate
for an episode of VF is more likely to be associated with
subsequent arrhythmic mortality.
In the AVID Trial, the majority of events were unrelated
to measurable ischemia, whether detected by patient symp-
toms, electrocardiographic changes or enzyme abnormali-
ties. In fact, only 4 of 79 arrhythmic deaths were associated
with markers of ischemia. This finding is consistent with
previous studies that have demonstrated that most arrhyth-
mic events are not necessarily associated with detectable
transient myocardial ischemia or an acute MI (22,23).
However, clinically inapparent ischemia as an arrhythmic
trigger in this population with a high prevalence of coronary
artery disease cannot be excluded. In the AVID Trial, 45 of
79 deaths classified as arrhythmic were unwitnessed, and
witnessed arrhythmic deaths usually occurred abruptly. Of-
ten, ECGs and enzymes were not obtained. The suddenness
and lack of objective laboratory data could account for some
of the apparent lack of manifest ischemia.
Nonarrhythmic deaths. In the AVID Trial, randomly
assigned therapy was expected to minimize treatment biases.
It would be expected that nonarrhythmic and noncardiac
deaths would be equal in patients treated with the ICD and
patients treated with an AAD, unless nonarrhythmic car-
diac deaths were increased in patients with an ICD because
these patients have a longer exposure time during which a
nonarrhythmic cardiac death could occur. However, no
survival advantage or disadvantage from the ICD was seen
for nonarrhythmic cardiac death. This finding is contrary to
what had been shown in some other studies where enroll-
ment bias might have been present. There was a small,
though statistically insignificant, difference in noncardiac
death, with a survival advantage in patients treated with the
ICD, compared with patients treated with an AAD. The
trend was not eliminated by adjusting for ejection fraction,
age, diabetes or history of CHF. This difference was
eliminated, however, when pulmonary deaths were cen-
sored. Thus, a possible explanation may be a deleterious
effect of AADs on noncardiac mortality, but if the pulmo-
Table 5. Final Classification: Events Committee Versus Principal Investigator
All Events
Principal Investigator
Cardiac Noncardiac
Events committee Cardiac 147 8
Noncardiac 4 40
Unable to classify 2 1
Cardiac events* Principal Investigator
Arrhythmic Nonarrhythmic
Events committee Arrhythmic 64 10
Nonarrhythmic 1 71
Unable to classify 0 1
*In cases where both Events Committee and Principal Investigator judged the event to be cardiac.
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nary deaths were indeed caused by AADs, then these deaths
should have been classified as cardiac.
Limitations. The use of beta-blocking drugs was imbal-
anced, with more patients in the ICD group receiving these
agents. Statistical adjustment for this covariate imbalance
did not affect the main result of the AVID Trial (the
primary end point being death from any cause), though it is
possible that beta-blockers could have affected the mecha-
nism of death.
In the AVID Trial, most arrhythmic deaths were out-of-
hospital. However, out-of-hospital events were also more
likely to be unwitnessed, perhaps leading to an overestimate
of the number of arrhythmic events. On the other hand,
hospitalized patients would be more likely to have a condi-
tion that would lead to a nonarrhythmic event, such as
CHF, cancer or pneumonia.
Conclusions. The ICD is an effective strategy to prevent
arrhythmic cardiac deaths. Despite this significant benefit, up
to 38% of cardiac deaths in patients treated with an ICD still
appeared to be arrhythmic. Nevertheless, applied to a suffi-
ciently high-risk population, the ICD is superior to an AAD.
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